Company: HROW
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022980
Chunk: 51

Company: HARROW, INC.
Filing Date: 2025-08-11
Form: 10-Q
Item: Item 1
Chunk 51
---
 customers accounted for 87% and 94%, respectively,
of total consolidated accounts receivable.

The
Company received its active pharmaceutical ingredients from three main suppliers during the three and six months ended June 30, 2025
and 2024. These suppliers collectively accounted for 76% and 72% of active pharmaceutical ingredient purchases during the three and six
months ended June 30, 2025, respectively, and 61% and 62% during the same periods in 2024, respectively.

    28

NOTE
15. SUBSEQUENT EVENTS

The
Company has performed an evaluation of events occurring subsequent to June 30, 2025 through the filing date of this Quarterly Report
on Form 10-Q. Based on its evaluation, no events other than those described below need to be disclosed.

In
July 2025, the Company issued 286,662 shares of common stock to Mark L. Baum, Chief Executive Officer, upon the cashless exercise of
options to purchase 600,000 shares at an exercise price of $7.87 per share. The Company withheld from Mr. Baum 127,346 shares as consideration
for the cashless exercise and an additional 185,992 shares for payroll tax obligations totaling $6,897,000.

In July 2025, the Company issued 795 shares
of common stock and received proceeds of $11,000 upon the exercise of options to purchase 795 shares of common stock with
exercise prices between $7.60 and $25.86 per share.

BYOOVIZ®
and OPUVIZTM – Commercialization Agreement

In
July 2025, the Company entered into a development and commercialization agreement (the “Samsung Agreement”) with Samsung
Bioepis Co., Ltd. (“Samsung”). Under the terms of the Samsung Agreement, following completion of the transition of commercial
rights from Biogen, Inc. back to Samsung, Samsung will develop, manufacture, and supply BYOOVIZ (ranibizumab-nuna) and OPUVIZ (aflibercept-yszy)
(individually, a “Product” and together, the “Products”) for Harrow to commercialize in the U.S. market (the
“Rights”). In consideration of such Rights, Harrow will make a one-time upfront payment to Samsung, and Samsung will be eligible
to receive additional one-time payments based on the achievement of net sales-based milestones of the